Overview
This reagent supplies two distinct research peptides in a single vial: CJC-1295 (no-DAC form, also referenced as modified GRF 1-29), a synthetic analog of growth-hormone-releasing hormone bearing stabilizing residue substitutions across its 29-amino-acid backbone, and ipamorelin, a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2). The two are chemically independent molecules that are not covalently linked; they are co-packaged because their targets sit on complementary receptor systems. CJC-1295 belongs to the GHRH/secretin peptide family, while ipamorelin is a member of the growth-hormone-secretagogue class. Both are produced synthetically as reference peptides for laboratory use.
Mechanism as studied
The research literature characterizes the pairing through concurrent engagement of two receptor systems on pituitary somatotrophs. CJC-1295 is described as an agonist at the GHRH receptor, a class-B G-protein-coupled receptor coupled to Gs/adenylate-cyclase and cyclic-AMP signaling, while ipamorelin engages the ghrelin/growth-hormone-secretagogue receptor (GHS-R1a), a Gq-coupled receptor linked to phospholipase-C and intracellular calcium mobilization. In cultured somatotroph and preclinical models, simultaneous activation of these convergent pathways is associated with additive or synergistic growth-hormone release relative to either peptide alone. Ipamorelin's receptor selectivity is noted in the literature for limited effect on cortisol and prolactin pathways.
Research context
Contexts in which this compound appears in the in-vitro and preclinical research literature:
- Pituitary somatotroph culture: cAMP and intracellular-calcium endpoints under dual GHRH-R and GHS-R stimulation.
- Comparative pharmacology of combined versus single-peptide exposure on growth-hormone secretion in preclinical models.
- Receptor-selectivity assays distinguishing ipamorelin's GHS-R engagement from ACTH and prolactin pathways.
- Enzymatic-stability studies of the modified GRF 1-29 backbone relative to native GHRH.
- Rodent models characterizing pulsatile growth-hormone dynamics and downstream IGF-1 signaling.
Handling & storage
Supplied as a co-lyophilized powder for laboratory reconstitution. Reconstitute with bacteriostatic water to the working concentration your assay requires (e.g. adding 2 mL to the 10 mg vial yields a combined 5 mg/mL). Introduce the diluent slowly against the vial wall and swirl gently to dissolve; do not shake or vortex. Aliquot after reconstitution to minimize freeze–thaw cycles.
Store the sealed lyophilized vial at −20 °C protected from light, where it is stable long-term. Refrigerate reconstituted material at 2–8 °C and avoid repeated freeze–thaw.
Certificates of analysis
Independent and in-house certificates published for this compound. Each reports identity and HPLC purity for the tested lot.
Order CJC-1295 + Ipamorelin Blend
Lot-traceable, certificate-backed, and shipped cold-chain from the US.
For research use only
This guide is reference material for qualified researchers. The compound is an analytical-grade reference material supplied strictly for in-vitro laboratory research and development — not a drug, supplement, or medical device, and not for human or animal consumption or any therapeutic, clinical, or diagnostic use. No medical claims are made or implied.
